Entinostat (MS-275)

製品コードS1053 別名:SNDX-275

Entinostat (MS-275)化学構造

分子量(MW):376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 24900.00
JPY 44820.00
JPY 127820.00

文献中Selleckの製品使用例(63)

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
ターゲット
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外試験

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\XUmlEPTB;MD6wOlEh|ryP NIGwNYpUSU6JRWK=
ALL-PO MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jyZmlEPTB;MD6wOlM2PSEQvF2= MlryV2FPT0WU
697 NFLGeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jxTWlEPTB;MD6wPVk4PiEQvF2= NUezfJF1W0GQR1XS
NCI-H748 M2n4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3PNGZKSzVyPUCuNVA{OzRizszN MknOV2FPT0WU
NKM-1 NX25eHllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMUC5NVIh|ryP MoG0V2FPT0WU
ES1 NUP0[oJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMUGyOVUh|ryP Mo\vV2FPT0WU
NCI-H1963 MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfacZpKSzVyPUCuNVE2PzlizszN MlzWV2FPT0WU
NCI-H1417 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMUK5O|Qh|ryP NW[0WI9LW0GQR1XS
NEC8 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMUO1Nlch|ryP NHTaU2hUSU6JRWK=
CRO-AP2 NHfuTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPFTWM2OD1yLkG2PFg6KM7:TR?= M17C[nNCVkeHUh?=
A3-KAW NIPEenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTPTVdKSzVyPUCuNVc3OjdizszN NUDSOWFnW0GQR1XS
SF539 NEPzVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrHTmZKSzVyPUCuNVk2QTNizszN MnPMV2FPT0WU
NOS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PJ[mlEPTB;MD6xPVYyQSEQvF2= MlfJV2FPT0WU
NTERA-S-cl-D1 NU\welhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LNfGlEPTB;MD6yNFEyOyEQvF2= M3vpVnNCVkeHUh?=
COR-L88 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjY[GhOUUN3ME2wMlIzQTV7IN88US=> MlnmV2FPT0WU
EM-2 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu3TWM2OD1yLkK0NFc6KM7:TR?= MnS1V2FPT0WU
KARPAS-45 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMke4N|Mh|ryP MULTRW5ITVJ?
DSH1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfCdVVTUUN3ME2wMlI5PzB6IN88US=> MknuV2FPT0WU
HT-144 NH2xbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwM{CyOVYh|ryP MlPqV2FPT0WU
ATN-1 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP6b|NKSzVyPUCuN|A2PzZizszN NGTlPJNUSU6JRWK=
HEL M4rLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwM{GzOFgh|ryP NG\tfotUSU6JRWK=
NB12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;3TWM2OD1yLkOxO|U3KM7:TR?= M1jR[3NCVkeHUh?=
LU-139 NXjnTlRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmzTWM2OD1yLkOzOVEh|ryP NI\Cc45USU6JRWK=
J-RT3-T3-5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOxTWM2OD1yLkOzO|E3KM7:TR?= MkPsV2FPT0WU
MOLT-13 M{PJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHWVmpKSzVyPUCuN|M5OSEQvF2= M33qSnNCVkeHUh?=
SR MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwM{SyOlEh|ryP NGr5S4ZUSU6JRWK=
CMK NFzZW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTwN4dSUUN3ME2wMlM2PzJ5IN88US=> Mnj6V2FPT0WU
ES8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO5TWM2OD1yLkO2NFIzKM7:TR?= M1zJPXNCVkeHUh?=
LB647-SCLC NH33dmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPGNm1KSzVyPUCuN|Y4OyEQvF2= NEXJR2xUSU6JRWK=
TE-8 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;0WJN3UUN3ME2wMlM3QTN3IN88US=> MlvxV2FPT0WU
BV-173 M3\6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hjb2lEPTB;MD6zO|EzOSEQvF2= NUPMSHJGW0GQR1XS
DEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm2NZVtUUN3ME2wMlM4PDh5IN88US=> M3\Ye3NCVkeHUh?=
ARH-77 M3zwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED4PG1KSzVyPUCuN|gyQTNizszN NUHweGhPW0GQR1XS
NCCIT M132W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwM{i2OFkh|ryP NXvGTWlqW0GQR1XS
RPMI-8402 NIrkSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjjTWM2OD1yLkO4O|AyKM7:TR?= M1jxcXNCVkeHUh?=
MONO-MAC-6 M2n4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwM{i3O|Yh|ryP NWHQbVRLW0GQR1XS
SK-MM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLCTHF[UUN3ME2wMlM6QDZ6IN88US=> NGrOb4lUSU6JRWK=
CHP-126 M2fMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fzZWlEPTB;MD60NFI{OSEQvF2= NEG5XpNUSU6JRWK=
A101D MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwNECzJO69VQ>? MV3TRW5ITVJ?
SCH MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P3dWlEPTB;MD60NFM1OiEQvF2= NYjLbnNHW0GQR1XS
NMC-G1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHmXYNKSzVyPUCuOFA{PjdizszN MULTRW5ITVJ?
NCI-H209 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DSR2lEPTB;MD60NFYyOyEQvF2= MVfTRW5ITVJ?
MOLT-16 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\MbWlEPTB;MD60NVAyPyEQvF2= MXTTRW5ITVJ?
RPMI-6666 NFjUT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwNEGxNkDPxE1? M2PlWXNCVkeHUh?=
OPM-2 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:4UG92UUN3ME2wMlQyPTF|IN88US=> M4LORXNCVkeHUh?=
MRK-nu-1 NXzyWFJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnsTWM2OD1yLkSzNVU{KM7:TR?= M3HTd3NCVkeHUh?=
BC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[wTWM2OD1yLkSzOFA{KM7:TR?= M2PIfHNCVkeHUh?=
MHH-NB-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ZTWM2OD1yLkSzOFU{KM7:TR?= NEX3XYtUSU6JRWK=
Ramos-2G6-4C10 NE\vd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrUcnlWUUN3ME2wMlQ{QDl5IN88US=> MXXTRW5ITVJ?
LS-513 M4nWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PkZmlEPTB;MD60OFUxOSEQvF2= NE\pd2JUSU6JRWK=
K5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn3[|ZKSzVyPUCuOFcxOjVizszN MVzTRW5ITVJ?
HOP-62 NESyXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwNEizOVgh|ryP M{PL[HNCVkeHUh?=
NCI-H187 NHXrXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHPTWM2OD1yLkS5NlI4KM7:TR?= M2PUbHNCVkeHUh?=
BE-13 M3\0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7JTWM2OD1yLkS5OlYyKM7:TR?= NVvhdnNpW0GQR1XS
HC-1 M16zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonoTWM2OD1yLkWwOFc{KM7:TR?= MlfpV2FPT0WU
ACN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP4UZZKSzVyPUCuOVExOjhizszN Mo\nV2FPT0WU
HCC1599 NV3hRZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwNUG1O{DPxE1? NVrSfIR{W0GQR1XS
MV-4-11 M{\ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwNUOwOFEh|ryP NFvZVJVUSU6JRWK=
LC-2-ad NX35WYZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVntc|JIUUN3ME2wMlU{PjZ|IN88US=> M1vwOXNCVkeHUh?=
HL-60 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHWcFlKSzVyPUCuOVQzPjFizszN NIK3WoVUSU6JRWK=
NB17 NG[3cJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHiV3pKSzVyPUCuOVQ{QCEQvF2= MoPyV2FPT0WU
TE-1 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33NO2lEPTB;MD61OVMxPiEQvF2= MVLTRW5ITVJ?
NCI-H524 NVvFWIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwNUW0NFEh|ryP MXTTRW5ITVJ?
MZ7-mel NGHFN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHrUFRzUUN3ME2wMlU3OTB3IN88US=> NHzQSVVUSU6JRWK=
L-363 M2D1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTke3lKSzVyPUCuOVY3PTdizszN NHXuNmtUSU6JRWK=
BL-41 NH3wUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwNU[4PFkh|ryP MVTTRW5ITVJ?
LU-134-A MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XaO2lEPTB;MD61O|A4OyEQvF2= NI\iNXdUSU6JRWK=
SIG-M5 NFPWcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHqO2JVUUN3ME2wMlU4QDR6IN88US=> NU\2RYVEW0GQR1XS
ONS-76 NFPjWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q4SWlEPTB;MD61PFI1OiEQvF2= Ml:yV2FPT0WU
KARPAS-299 NXLhToxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrkN2d2UUN3ME2wMlU5PTB2IN88US=> M3fWSXNCVkeHUh?=
DU-4475 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHZTWM2OD1yLkW4O|A{KM7:TR?= NEDlfHRUSU6JRWK=
NB69 M2W4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrwS|BKSzVyPUCuOVk5OjVizszN MUnTRW5ITVJ?
MHH-PREB-1 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\5WVlKSzVyPUCuOlA4OTlizszN M3fNS3NCVkeHUh?=
LU-165 NHvGTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\iTWM2OD1yLk[xPFEzKM7:TR?= NW\iR3dZW0GQR1XS
LOUCY NWLOWnlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXSzc2c5UUN3ME2wMlY{OzZ2IN88US=> MXrTRW5ITVJ?
NCI-H526 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPiTWM2OD1yLk[zOVQyKM7:TR?= NHr3VlZUSU6JRWK=
KE-37 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH0OHRKSzVyPUCuOlQzPzZizszN MmXiV2FPT0WU
NALM-6 NVzFU3Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwNkS4OkDPxE1? NHfzU|BUSU6JRWK=
CW-2 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwNkW3PVQh|ryP MmHyV2FPT0WU
SU-DHL-1 MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnEcodQUUN3ME2wMlY2QTR5IN88US=> M3LuVnNCVkeHUh?=
NB13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uxemlEPTB;MD62OlgyPyEQvF2= NFP0[HFUSU6JRWK=
QIMR-WIL Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnv[I16UUN3ME2wMlY5OzR|IN88US=> MkHWV2FPT0WU
ECC12 NUXYelBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2zdlRKSzVyPUCuO|AxQDZizszN NEHzTVhUSU6JRWK=
KALS-1 NGjJUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3uWoxNUUN3ME2wMlcxPDl{IN88US=> MYjTRW5ITVJ?
COR-L279 NVnWNXZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi5TWM2OD1yLkewPVk3KM7:TR?= MnL0V2FPT0WU
NB14 NVficnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PuS2lEPTB;MD63NlYyPyEQvF2= MkO0V2FPT0WU
CCRF-CEM NFn4dVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwN{S2OlEh|ryP NUfBSnRPW0GQR1XS
SW954 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXreIRFUUN3ME2wMlc2QTl7IN88US=> MX3TRW5ITVJ?
IST-SL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[4NJVKSzVyPUCuO|c{PDhizszN NYfOU2NxW0GQR1XS
LAMA-84 MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwN{e1Olch|ryP MWTTRW5ITVJ?
Daudi MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLwT2tPUUN3ME2wMlc4PjhzIN88US=> NF;qPHBUSU6JRWK=
BC-3 M2fl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LxTWlEPTB;MD63PFMxQCEQvF2= MVnTRW5ITVJ?
HCC2998 NUT3emV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ncGlEPTB;MD63PFM3KM7:TR?= M{TlXHNCVkeHUh?=
NCI-H69 M1zJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLwUIhKSzVyPUCuPFAyPDdizszN NXW1eIJSW0GQR1XS
CPC-N NX:4SWdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjXN3hnUUN3ME2wMlgxPTJ2IN88US=> MU\TRW5ITVJ?
NOMO-1 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HWSmlEPTB;MD64NVA5PCEQvF2= NF7p[3BUSU6JRWK=
CESS MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj0TWM2OD1yLkixNVk4KM7:TR?= Ml\6V2FPT0WU
LC4-1 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e4OWlEPTB;MD64OFAxPyEQvF2= M{jlPHNCVkeHUh?=
BL-70 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jiUGlEPTB;MD64OVcxOiEQvF2= NX;VXXJRW0GQR1XS
ES4 NIrRPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXhVYd6UUN3ME2wMlg2QDZ6IN88US=> NXnYSlZnW0GQR1XS
HCE-T NFnPOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TmfGlEPTB;MD64O|E4OSEQvF2= M2nKOHNCVkeHUh?=
JAR MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwOEe4Nlch|ryP MX;TRW5ITVJ?
ST486 NFe5d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;ISYhKSzVyPUCuPFc6OTdizszN NGLCNJFUSU6JRWK=
KS-1 M{n1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXWTWM2OD1yLki4NFk3KM7:TR?= NVHmZXZ4W0GQR1XS
GDM-1 NULIWXN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3nTo12UUN3ME2wMlg5Pjh5IN88US=> NVf4eHNpW0GQR1XS
EHEB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwOUK1PFUh|ryP M{fteXNCVkeHUh?=
LB2518-MEL M162T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SwUmlEPTB;MD65N|I5PCEQvF2= M1X5UnNCVkeHUh?=
GOTO MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXHTWM2OD1yLkm1NFc3KM7:TR?= MXzTRW5ITVJ?
LXF-289 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwOUW5NFEh|ryP M4HxU3NCVkeHUh?=
ES6 NH64VpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwOU[0N|ch|ryP NX7VPFQ2W0GQR1XS
OS-RC-2 M2CyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXFe2ZKSzVyPUCuPVY5OyEQvF2= NHHq[JFUSU6JRWK=
DMS-153 M{C4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:0cIFKSzVyPUCuPVc1PjlizszN M4q2NHNCVkeHUh?=
SK-PN-DW NV[1UldPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TWS2lEPTB;MD65O|g{OSEQvF2= NG\XSnVUSU6JRWK=
HH Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwOUi5OVkh|ryP MUPTRW5ITVJ?
SH-4 MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwMEK0NUDPxE1? NH7QNnZUSU6JRWK=
MOLT-4 NIDKbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjKOYhKSzVyPUGuNFM1PTRizszN MXvTRW5ITVJ?
TGW NV;M[GlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPuPXVtUUN3ME2xMlA4Pjd3IN88US=> MYfTRW5ITVJ?
L-540 NX20WG1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwMUC2NFQh|ryP M1fl[3NCVkeHUh?=
PF-382 NGHjeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nFbGlEPTB;MT6xNVUyOyEQvF2= MV7TRW5ITVJ?
LC-1F NHLDXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q1R2lEPTB;MT6xNlAxPyEQvF2= M3KzfnNCVkeHUh?=
OVCAR-4 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DwTGlEPTB;MT6xN|E3PSEQvF2= MkS0V2FPT0WU
A4-Fuk NF;kWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3CeY9KSzVyPUGuNVU{PjRizszN NYfZR3E5W0GQR1XS
HCC2218 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ZTWM2OD1zLkG2OlQyKM7:TR?= NHLOUGtUSU6JRWK=
HAL-01 NYrLTlJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwMU[5OFMh|ryP Ml7OV2FPT0WU
IST-MEL1 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfyZ5VyUUN3ME2xMlE4PjV7IN88US=> NGqzVWRUSU6JRWK=
NCI-H719 Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPjZZhbUUN3ME2xMlE4QDl6IN88US=> MY\TRW5ITVJ?
EVSA-T MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwMUixNVQh|ryP MXzTRW5ITVJ?
SK-NEP-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[yWIJKSzVyPUGuNlAzPjZizszN MlzqV2FPT0WU
OCUB-M M3P0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXCdpdKSzVyPUGuNlE1QDlizszN M{LwXHNCVkeHUh?=
MEG-01 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfEZosyUUN3ME2xMlIzOTF6IN88US=> M2e1WnNCVkeHUh?=
no-10 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHvTWM2OD1zLkKzNVEzKM7:TR?= NHXMb|hUSU6JRWK=
MHH-CALL-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\EbXhKSzVyPUGuNlQ4OjFizszN MXvTRW5ITVJ?
SK-N-DZ MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLzTWM2OD1zLkK0O|c3KM7:TR?= MWPTRW5ITVJ?
SCLC-21H MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLafVE5UUN3ME2xMlI3PDd6IN88US=> MmDrV2FPT0WU
CTV-1 M2TkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofGTWM2OD1zLkK3OFI2KM7:TR?= MoTRV2FPT0WU
NB1 NYfkfIF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwMke3N|Ih|ryP NECzZnpUSU6JRWK=
NCI-H64 NH\LRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfHTWM2OD1zLkK4OFYzKM7:TR?= M3nKcXNCVkeHUh?=
MDA-MB-134-VI M4LYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;uTWM2OD1zLkK4OVc4KM7:TR?= MkTFV2FPT0WU
LB2241-RCC Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{WyTmlEPTB;MT6yPFY3OyEQvF2= NVLiNoRnW0GQR1XS
8-MG-BA M3jNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwMki4OlYh|ryP NXH6V451W0GQR1XS
LP-1 M3XvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTncXZGUUN3ME2xMlI6QTR5IN88US=> MX;TRW5ITVJ?
LS-411N NH7JZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjL[opKSzVyPUGuN|A6QThizszN MkPVV2FPT0WU
CAL-148 MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXmfJpWUUN3ME2xMlMzPTR{IN88US=> MnXMV2FPT0WU
NCI-H2171 MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjPcWRKSzVyPUGuN|Q2ODJizszN Mn3tV2FPT0WU
JiyoyeP-2003 Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fi[mlEPTB;MT6zOVM6KM7:TR?= NWfle3pSW0GQR1XS
NCI-H2107 NUizeHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;vNWlEPTB;MT6zOVg5OyEQvF2= NFXaPXVUSU6JRWK=
BB30-HNC MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;xR2lEPTB;MT6zPFk4QCEQvF2= M4[yWXNCVkeHUh?=
K-562 NW\JSpRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j5OGlEPTB;MT6zPVIyQSEQvF2= MnTtV2FPT0WU
PSN1 NW\HN2VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\RTWM2OD1zLkSyNlg4KM7:TR?= NXPRNGpTW0GQR1XS
HCC2157 NUPsdXQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{exdGlEPTB;MT60NlY6OSEQvF2= MoXzV2FPT0WU
SBC-1 NFS2fmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr4OIVKSzVyPUGuOFI4PDFizszN NE[0e25USU6JRWK=
MC116 NYrNZ3JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDjO|hxUUN3ME2xMlQ{PjF3IN88US=> M1zEZ3NCVkeHUh?=
KARPAS-422 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jtVGlEPTB;MT60OVM2QCEQvF2= NULiRoVHW0GQR1XS
LB996-RCC MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nVOGlEPTB;MT60O|ExOyEQvF2= NULHSpM5W0GQR1XS
MSTO-211H NXjIPGIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwNEe5PFch|ryP M4ftSHNCVkeHUh?=
BT-474 NEfTRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf4VZd5UUN3ME2xMlUyPzZ2IN88US=> MXrTRW5ITVJ?
A388 M2G5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DBfGlEPTB;MT61NVk1PSEQvF2= M4P2c3NCVkeHUh?=
SJSA-1 M1nkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfmTWM2OD1zLkWyNlYh|ryP MorRV2FPT0WU
COLO-829 NGPPWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwNUO1OlQh|ryP NVHrdpI{W0GQR1XS
KM-H2 NUjyZpBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH61R5NKSzVyPUGuOVY3PyEQvF2= MlTCV2FPT0WU
GR-ST MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPHTWM2OD1zLkW2PFIh|ryP M1;5OnNCVkeHUh?=
RPMI-8866 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwNkCxOFQh|ryP Mlu0V2FPT0WU
KG-1 NFXLR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH33cpNKSzVyPUGuOlE6ODFizszN NIeySpFUSU6JRWK=
NCI-H82 NF;OeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwNkO0NFYh|ryP NUKzVZhHW0GQR1XS
LB1047-RCC NYGyN|BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXFRY9uUUN3ME2xMlY{PDV7IN88US=> M4PaSHNCVkeHUh?=
KM12 M2WxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwNkS3JO69VQ>? MXPTRW5ITVJ?
NB5 NFPPWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwNkW2O|ch|ryP NH7HTZhUSU6JRWK=
HDLM-2 M2HrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M162fWlEPTB;MT62PFI5OSEQvF2= M{HGU3NCVkeHUh?=
KU812 M{SwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC2TWM2OD1zLk[5OlA2KM7:TR?= M3rNXXNCVkeHUh?=
DB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLqcVlKSzVyPUGuO|A{PTNizszN NETOVWdUSU6JRWK=
HD-MY-Z M3jLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LZOmlEPTB;MT63OVI{PCEQvF2= M1GxeXNCVkeHUh?=
KURAMOCHI MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\ORWlEPTB;MT63O|IxPyEQvF2= NUXwVYUyW0GQR1XS
ETK-1 NV:z[Yk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvCTWM2OD1zLke4PFc6KM7:TR?= NIXOZ2NUSU6JRWK=
SK-UT-1 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3OTWM2OD1zLke5N|g5KM7:TR?= MVPTRW5ITVJ?
HUTU-80 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnRTWM2OD1zLke5OVA5KM7:TR?= MmL2V2FPT0WU
ES7 M2HT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwOECzNFIh|ryP NWPxR|N3W0GQR1XS
SW872 Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrCS2ZKSzVyPUGuPFE{QTVizszN M{TXN3NCVkeHUh?=
TK10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwOEOxNFgh|ryP M4P3dHNCVkeHUh?=
LB831-BLC NXvLTHF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfucml4UUN3ME2xMlg{PTZ|IN88US=> NX7EWG9TW0GQR1XS
TE-9 NEfIUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\QeJo6UUN3ME2xMlg1PDJ{IN88US=> M4DKdHNCVkeHUh?=
MLMA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LodWlEPTB;MT64PFI{PCEQvF2= M{fpb3NCVkeHUh?=
D-542MG Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInmb3NKSzVyPUGuPFk{PzNizszN M2ryfXNCVkeHUh?=
EW-16 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7KXYdKSzVyPUGuPVI4OiEQvF2= M1\4cXNCVkeHUh?=
LOXIMVI MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwOUOyPEDPxE1? NVHFelhTW0GQR1XS
GB-1 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwOUO4OlYh|ryP NFruSHRUSU6JRWK=
IST-SL2 NUXxZVJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\LSJdKSzVyPUKuNFAzPjJizszN MnLUV2FPT0WU
LAN-6 NX\K[GdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ziVmlEPTB;Mj6wNVk3PiEQvF2= NF3QWGlUSU6JRWK=
NCI-H510A M1TTRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKwTHBKSzVyPUKuNFQ2ODJizszN MVzTRW5ITVJ?
NCI-H1092 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LFd2lEPTB;Mj6wOVEzPCEQvF2= MV;TRW5ITVJ?
HT NEDWco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnVTWM2OD1{LkGwOFU1KM7:TR?= MnXhV2FPT0WU
RL95-2 NV\FPIpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET2XWNKSzVyPUKuNVE1QDJizszN NUTSTlU2W0GQR1XS
NCI-H1355 NHTlSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L1b2lEPTB;Mj6xNVc6OiEQvF2= NUTLOpl1W0GQR1XS
NCI-H720 M3jRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnrd2tOUUN3ME2yMlE3QDd|IN88US=> MlrMV2FPT0WU
NCI-H1522 M3[1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjpTWM2OD1{LkKxO|I{KM7:TR?= MknsV2FPT0WU
LB373-MEL-D MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPhcFBKSzVyPUKuNlY6ODJizszN M4XrZ3NCVkeHUh?=
DG-75 NV;UN2tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jYfmlEPTB;Mj6yO|E1QCEQvF2= NH3uTIZUSU6JRWK=
ML-2 NVz4[5ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn0TWM2OD1{LkOyPFU2KM7:TR?= NU\tZ4RZW0GQR1XS
SF126 NIq4N4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS1eJNKSzVyPUKuN|MxQTRizszN M1;yWnNCVkeHUh?=
MPP-89 NYXMcXQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M322dGlEPTB;Mj6zN|E1PSEQvF2= MWDTRW5ITVJ?
NCI-H345 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\4ZmlEPTB;Mj6zN|I4PyEQvF2= NEn4NnBUSU6JRWK=
LS-123 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJwM{S5N|Yh|ryP MnrjV2FPT0WU
NB10 M1H5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\QSnhtUUN3ME2yMlQyODl{IN88US=> NGnYeZFUSU6JRWK=
CGTH-W-1 NVzyfW9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwNEKyOlch|ryP NYK5O5JnW0GQR1XS
CP66-MEL NXH3RZFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnEU2dKSzVyPUKuOFc4PyEQvF2= M2\PUnNCVkeHUh?=
L-428 NVvQUWFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwNEi1NlEh|ryP NVXOeot{W0GQR1XS
DMS-79 M1rRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTjeZdKSzVyPUKuOVQyODNizszN MWjTRW5ITVJ?
NCI-H1882 MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PBRmlEPTB;Mj62O|U3OiEQvF2= MVTTRW5ITVJ?
KGN NVfLOYJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnuTWM2OD1{Lke2PFc3KM7:TR?= NYLYZ4RlW0GQR1XS
EW-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTjTWM2OD1{Lke3NFg{KM7:TR?= M17QV3NCVkeHUh?=
U-266 M1XkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\FTWM2OD1{Lki0PFI{KM7:TR?= M3myXHNCVkeHUh?=
COLO-320-HSR NVPwbm5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwOEW2OFEh|ryP NXT3XFFVW0GQR1XS
KMOE-2 NUnoeJU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PYcWlEPTB;Mj64O|cyOSEQvF2= MmHGV2FPT0WU
BB49-HNC MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJwOUK0PEDPxE1? MX;TRW5ITVJ?
GI-1 M2DPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnTZVFKSzVyPUKuPVI6PTdizszN M2Ts[XNCVkeHUh?=
NCI-H1304 NXG0TG9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonSTWM2OD1|LkCwOVEyKM7:TR?= Mnr5V2FPT0WU
NCI-H2227 NH:zeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHzUGlKSzVyPUOuNFIxPzlizszN MU\TRW5ITVJ?
U-87-MG MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTNwMEO1NVMh|ryP MXrTRW5ITVJ?
NCI-H747 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm3[ndKSzVyPUOuNFUzODZizszN M3\mdnNCVkeHUh?=
CTB-1 NF3MOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nkS2lEPTB;Mz6wOVM4PiEQvF2= M1rSXXNCVkeHUh?=
RPMI-8226 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnpWXRKSzVyPUOuNVQ{PzhizszN M1zUSHNCVkeHUh?=
NCI-H2141 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTNwMU[1OlYh|ryP MV\TRW5ITVJ?
IST-MES1 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDjTWM2OD1|LkG4Nlc6KM7:TR?= NXnIW4Z2W0GQR1XS
TE-5 M1LYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorWTWM2OD1|LkKxN|QzKM7:TR?= NY\heYs1W0GQR1XS
UACC-257 M3\Ub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNwNEO2OVkh|ryP NWPpXYJTW0GQR1XS
SK-N-FI M3G2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPGcHdKSzVyPUOuOFUzOjdizszN MkXiV2FPT0WU
MFH-ino NVu0dGpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPITWM2OD1|LkS2OVg6KM7:TR?= MXXTRW5ITVJ?
SF268 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDUbYFqUUN3ME2zMlQ5OTd2IN88US=> NXnDXoROW0GQR1XS
TE-12 NIXkfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfyTWM2OD1|LkWxOlk6KM7:TR?= NWGwSnNIW0GQR1XS
NB6 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\obFYxUUN3ME2zMlU2PTZ|IN88US=> NFS3e|RUSU6JRWK=
DJM-1 NYjTRZBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTNwNUm4PVkh|ryP MWrTRW5ITVJ?
MZ1-PC NWHKW5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Tyd2lEPTB;Mz62NVYzPCEQvF2= MlTlV2FPT0WU
OCI-AML2 M{LPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzQ[HRKSzVyPUOuOlI3PzFizszN NHPCZ45USU6JRWK=
NCI-H1155 M1HpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNwN{C5OFch|ryP MXrTRW5ITVJ?
RKO MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPBdFJPUUN3ME2zMlc4OTh7IN88US=> NHvaeHZUSU6JRWK=
ECC4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3TOXplUUN3ME2zMlk4OTl3IN88US=> M3PDeXNCVkeHUh?=
BB65-RCC NVXGeIxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTNwOUe1OFch|ryP M3PlbHNCVkeHUh?=
EB-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrw[mtXUUN3ME2zMlk6PjN|IN88US=> Ml\6V2FPT0WU
SHP-77 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTRwMEC1NlQh|ryP MlHIV2FPT0WU
NCI-H2196 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTRwMEW2NlUh|ryP NFLLd3NUSU6JRWK=
GI-ME-N Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\OR2lEPTB;ND6wOlM6QSEQvF2= NF;5fXFUSU6JRWK=
MN-60 Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7Udmg3UUN3ME20MlExQDdizszN NVjkWGRJW0GQR1XS
NCI-H1694 NGPyT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\lUGlEPTB;ND6xN|QxPSEQvF2= MmDVV2FPT0WU
LU-65 NH62NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX4T5BXUUN3ME20MlE2OzN{IN88US=> NF7nXG5USU6JRWK=
NCI-H1436 NIHLcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTRwMUizN|Mh|ryP M2nPZXNCVkeHUh?=
KINGS-1 NFz4[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnGc2FKUUN3ME20MlMyPDN{IN88US=> MnG1V2FPT0WU
GT3TKB MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[1PGlEPTB;ND6zN|I3QCEQvF2= NELL[o1USU6JRWK=
Becker MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XuemlEPTB;ND6zO|MyOiEQvF2= NHrKdHZUSU6JRWK=
HCC1187 MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRwOEm2OVch|ryP M1WyVHNCVkeHUh?=
D-502MG M3j6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\xTWM2OD13LkCwOFE3KM7:TR?= NYXhSYVVW0GQR1XS
VA-ES-BJ M3XCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTJTnRSUUN3ME21MlE{Pzd6IN88US=> MV\TRW5ITVJ?
NB7 NVntTVdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXEXZFKSzVyPUWuNVQyOTJizszN MlvlV2FPT0WU
SW962 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXGfppKSzVyPUWuN|g5OTRizszN NYDDO41bW0GQR1XS
no-11 M2TlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\uTWM2OD13Lke2N|Q{KM7:TR?= MkLvV2FPT0WU
KNS-81-FD M3K5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;BfWlEPTB;NT65NFY6PCEQvF2= MYTTRW5ITVJ?
COLO-684 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTVwOUm0PVQh|ryP M{XQPHNCVkeHUh?=
D-263MG NXHZS|I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPYbWhKSzVyPU[uNFg5QTVizszN M3;KS3NCVkeHUh?=
EW-24 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTZwMki1NUDPxE1? NIjteoRUSU6JRWK=
TE-10 M4n3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTZwNEK2NlMh|ryP NVzYTJRKW0GQR1XS
EKVX NXTsboxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xic2lEPTB;Nj60OlMzOSEQvF2= MonVV2FPT0WU
NCI-H1648 M16zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTZwNke1OVch|ryP M4nFSHNCVkeHUh?=
LB771-HNC NUTlUXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jWZ2lEPTB;Nj65NlMxOSEQvF2= MnvVV2FPT0WU
SK-MEL-1 M4Hxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:2fFN6UUN3ME24MlE{OTZ4IN88US=> NFq1UnNUSU6JRWK=
COLO-668 NIDvRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXsUZhzUUN3ME24MlI4Pzh4IN88US=> MlnVV2FPT0WU
EW-12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRThwNEC4NFMh|ryP MUTTRW5ITVJ?
A253 NFLoU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnoRWVKSzVyPUiuPFQ3PjFizszN NUOxVHIzW0GQR1XS
NCI-H2126 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnWV4ZMUUN3ME24Mlg6OzF7IN88US=> NFPw[oVUSU6JRWK=
Calu-6 NH;iWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfJ[pM3UUN3ME24Mlk6ODR{IN88US=> NWXF[5lvW0GQR1XS
NCI-H23 NHv3T5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPBTWM2OD17LkG3O|Q3KM7:TR?= M{L1e3NCVkeHUh?=
WSU-NHL M1Tme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P4b2lEPTB;OT63O|Q4QCEQvF2= NUfMdoZZW0GQR1XS
MMAC-SF MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlywTWM2OD17Lkm3PVA1KM7:TR?= Mnz0V2FPT0WU
SK-LMS-1 M3fuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nhcmlEPTB;MUCuNlg{PCEQvF2= NGD0UoFUSU6JRWK=
GCIY MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm0TWM2OD1zMD61PVI1KM7:TR?= MnLiV2FPT0WU
TE-15 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH2OGlKSzVyPUGxMlYxODRizszN NXH3ZYxQW0GQR1XS
EoL-1-cell M3PEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFzLke2PFIh|ryP NVWzb2FtW0GQR1XS
NCI-H2081 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPxNIxKSzVyPUGxMlc4QDZizszN NGXuOnNUSU6JRWK=
EW-3 NFTIdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF{LkK0OlMh|ryP MVTTRW5ITVJ?
CAS-1 NVzZ[JE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjScpl{UUN3ME2xNk4{PjNzIN88US=> NHjaWpdUSU6JRWK=
C2BBe1 NF25e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF{Lk[xN|Eh|ryP MXfTRW5ITVJ?
D-247MG M4rpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF{Lke5OVIh|ryP M4juOHNCVkeHUh?=
NCI-SNU-5 NVPCcFA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzxcI5KSzVyPUGyMlgxOTNizszN MonDV2FPT0WU
LS-1034 NHW1bZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlflTWM2OD1zND6zPVc2KM7:TR?= NH70S29USU6JRWK=
EW-18 NHnFZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm2No1KSzVyPUG0MlQ1QCEQvF2= MljKV2FPT0WU
Raji MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW5TWM2OD1zND61NFQ6KM7:TR?= MWTTRW5ITVJ?
D-283MED M{DseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu3TWM2OD1zND62NlcyKM7:TR?= MUTTRW5ITVJ?
MZ2-MEL MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi3ZmNKSzVyPUG0Mlk3QTZizszN NGWzc49USU6JRWK=
NCI-SNU-16 NY\XeVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7YflVKSzVyPUG1MlQ3OzNizszN M3jieHNCVkeHUh?=
P30-OHK NX;veZlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF5Lke4N|Eh|ryP MoXiV2FPT0WU
RXF393 M2fk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH1TWM2OD1zOT6wNVg3KM7:TR?= MXzTRW5ITVJ?
NCI-H1395 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrlTWM2OD1{MD62O|A{KM7:TR?= M13I[HNCVkeHUh?=
U-698-M MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWToXWRnUUN3ME2yNE44ODd3IN88US=> NISwbFJUSU6JRWK=
NCI-SNU-1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJyLkeyNlMh|ryP MlPJV2FPT0WU
SW684 M1fnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fZXWlEPTB;MkGuNVcyPiEQvF2= M{DaSnNCVkeHUh?=
NCI-H716 NEm5eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\xO2lEPTB;MkGuN|E2PCEQvF2= MnviV2FPT0WU
JVM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jHTGlEPTB;MkGuOFE{OyEQvF2= M4LKbXNCVkeHUh?=
NCI-H1581 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ{LkSxOFgh|ryP NHnlNotUSU6JRWK=
CA46 M{LGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTOOoxtUUN3ME2zNU43QTN4IN88US=> NYKxboZ7W0GQR1XS
SNB75 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTN|Lk[1NFMh|ryP MmrsV2FPT0WU
KNS-42 MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnlbo45UUN3ME2zOU46PjJ2IN88US=> NV3oVGh7W0GQR1XS
TUR NUC0PYxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvtV21yUUN3ME2zOk4xPTJzIN88US=> NVvkO|hFW0GQR1XS
REH NWXEN3djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XVVmlEPTB;M{euPFIyOSEQvF2= MkLVV2FPT0WU
EW-22 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\mTWM2OD12Mj6yPFg2KM7:TR?= MWfTRW5ITVJ?
NCI-H446 NVz2VnFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW4TJNKSzVyPUSyMlc5PTNizszN MmrlV2FPT0WU
ES3 NXjXT451T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITWd5BKSzVyPUSzMlE{OzlizszN NH3NT5ZUSU6JRWK=
EW-11 M2LvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDBfIxKSzVyPUS0MlgzOThizszN M1;pe3NCVkeHUh?=
RH-1 M{DDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fweWlEPTB;NEeuOVgyOiEQvF2= MVTTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
体内試験 MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[6]

+ 展開

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
細胞試験:

[2]

+ 展開
  • 細胞株: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • 濃度: ~ 10 μM
  • 反応時間: 3 days
  • 実験の流れ:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • 製剤: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • 投薬量: 12.3, 24.5 and 49 mg/kg
  • 投与方法: Administered orally once daily 5 days per week for 4 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 376.41
化学式

C21H20N4O3

CAS No. 209783-80-2
保管
in solvent
別名 SNDX-275

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Entinostat (MS-275)を買う | Entinostat (MS-275) ic50 | Entinostat (MS-275)供給者 | Entinostat (MS-275)を購入する | Entinostat (MS-275)費用 | Entinostat (MS-275)生産者 | オーダーEntinostat (MS-275) | Entinostat (MS-275)化学構造 | Entinostat (MS-275)分子量 | Entinostat (MS-275)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID